Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.
PatientView 2016 ranks Novartis in top 3 companies with best reputation among patient groups
On March 21, 2017, PatientView released their "Corporate Reputation of Pharma in 2016; The Patient Perspective." Novartis is honored to be amongst the top 3 companies with the best corporate reputation among patient groups in 2016. Novartis is also proud to be recognized as the number one partner for patient groups, having worked with 395 groups in the past five years. Novartis places second in "corporate brand awareness" amongst patient groups. PatientView's results are based on a survey among 1,463 patient groups from 105 countries.
Novartis is featured as one of the 2016 “Top 100 Global Innovators”
Novartis is featured as one of the 2016 “Top 100 Global Innovators,” as compiled by Clarivate Analytics (formerly the “IP & Science” division of Thomson Reuters). Novartis is listed for the third consecutive time.
Novartis on FORTUNE's list of the World's Most Admired Companies
Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.
Novartis ranks third in 2016 Access to Medicine Index
Novartis ranked third in the 2016 Access to Medicine Index, up from 4th place in 2014. We topped the industry in access-to-medicine management and capacity building, and our integrated access strategy addressing all income segments stood out as best practice.
Two Novartis products receive 2016 Prix Galien Foundation Awards
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate).
Novartis included in Dow Jones Sustainability World Index
Novartis is proud to again be included in the Dow Jones Sustainability World Index, and to be recognized for its efforts in sustainability. The Index is an annual evaluation of the sustainability practices of 3400 of the world’s largest listed companies. Companies are listed in the annual ranking if they are best in class within their industry for sustainability.
Novartis has been ranked among the top green companies in the world by 2016 Newsweek Green Rankings. Since 2009, the Newsweek Green Rankings, created in partnership with Corporate Knights and HIP Investor, have been one of the world’s foremost corporate environmental rankings which assess the 500 largest publicly-traded companies in the United States and the 500 largest publicly-traded companies globally on overall environmental performance.
Novartis among 2016 Global 100 Most Sustainable Corporations list by Corporate Knights
The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using 12 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
Novartis has been named as one of the world’s most innovative companies, for the second year running. The company is included in the Thomson Reuters 2015 Top 100 Global Innovators rankings. This independent recognition is based on a proprietary methodology to identify the most influential organizations globally as demonstrated through patent and intellectual property data.